The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …

Adenosine A 2A receptor antagonists represent a new way forward in the symptomatic
treatment of Parkinson's disease (PD) through a non-dopaminergic mechanism. As a class …

Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine,
glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and …

Long-term disability in Parkinson's disease (PD) is related to progression of the underlying
disease and the emergence of complications of chronic levodopa therapy. There is a need …

Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder. To
date, most of the currently available therapies in PD target the dopaminergic system and …

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder,
affecting up to 10 million people worldwide. Current treatment primarily involves symptom …

The drug treatment of Parkinson's disease (PD) is accompanied by a loss of drug efficacy,
the onset of motor complications, lack of effect on non-motor symptoms, and a failure to …

The moderate and severe stages of Parkinson's disease (PD) are marked by motor and non-
motor complications that still remain difficult to control with the currently available therapy …

Adenosine A2A receptors present in the central nervous system have been implicated in the
modulation of motor functions. Accordingly, adenosine A2A receptor antagonists currently …

In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …